Skip to main content

Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.

Publication ,  Journal Article
Bean, GR; Ibarra Drendall, C; Goldenberg, VK; Baker, JC; Troch, MM; Paisie, C; Wilke, LG; Yee, L; Marcom, PK; Kimler, BF; Fabian, CJ; Scott, V ...
Published in: Cancer Epidemiol Biomarkers Prev
January 2007

Mutation of the breast cancer-associated gene 1 (BRCA1) plays an important role in familial breast cancer. Although hypermethylation of the BRCA1 promoter has been observed in sporadic breast cancer, its exact role in breast cancer initiation and association with breast cancer risk is unknown. The frequency of BRCA1 promoter hypermethylation was tested in (a) 14 primary breast cancer biopsies and (b) the initial random periareolar fine-needle aspiration (RPFNA) cytologic samples obtained from 61 asymptomatic women who were at increased risk for breast cancer. BRCA1 promoter hypermethylation was assessed from nucleotide -150 to nucleotide +32 relative to the transcription start site. RPFNA specimens were stratified for cytologic atypia using the Masood cytology index. BRCA1 promoter hypermethylation was observed at similar frequency in nonproliferative (normal; Masood

Duke Scholars

Published In

Cancer Epidemiol Biomarkers Prev

DOI

ISSN

1055-9965

Publication Date

January 2007

Volume

16

Issue

1

Start / End Page

50 / 56

Location

United States

Related Subject Headings

  • Risk Factors
  • Promoter Regions, Genetic
  • Predictive Value of Tests
  • Middle Aged
  • Hyperplasia
  • Humans
  • Genetic Predisposition to Disease
  • Genes, BRCA1
  • Female
  • Epidemiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bean, G. R., Ibarra Drendall, C., Goldenberg, V. K., Baker, J. C., Troch, M. M., Paisie, C., … Seewaldt, V. L. (2007). Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. Cancer Epidemiol Biomarkers Prev, 16(1), 50–56. https://doi.org/10.1158/1055-9965.EPI-06-0598
Bean, Gregory R., Catherine Ibarra Drendall, Vanessa K. Goldenberg, Joseph C. Baker, Michelle M. Troch, Carolyn Paisie, Lee G. Wilke, et al. “Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.Cancer Epidemiol Biomarkers Prev 16, no. 1 (January 2007): 50–56. https://doi.org/10.1158/1055-9965.EPI-06-0598.
Bean GR, Ibarra Drendall C, Goldenberg VK, Baker JC, Troch MM, Paisie C, et al. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):50–6.
Bean, Gregory R., et al. “Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.Cancer Epidemiol Biomarkers Prev, vol. 16, no. 1, Jan. 2007, pp. 50–56. Pubmed, doi:10.1158/1055-9965.EPI-06-0598.
Bean GR, Ibarra Drendall C, Goldenberg VK, Baker JC, Troch MM, Paisie C, Wilke LG, Yee L, Marcom PK, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Scott V, Seewaldt VL. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):50–56.

Published In

Cancer Epidemiol Biomarkers Prev

DOI

ISSN

1055-9965

Publication Date

January 2007

Volume

16

Issue

1

Start / End Page

50 / 56

Location

United States

Related Subject Headings

  • Risk Factors
  • Promoter Regions, Genetic
  • Predictive Value of Tests
  • Middle Aged
  • Hyperplasia
  • Humans
  • Genetic Predisposition to Disease
  • Genes, BRCA1
  • Female
  • Epidemiology